EJMK Ventures LLC Purchases Shares of 5,667 Merck & Co., Inc. $MRK

EJMK Ventures LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,667 shares of the company’s stock, valued at approximately $596,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MRK. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. in the fourth quarter valued at about $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. in the fourth quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in Merck & Co., Inc. in the third quarter worth about $31,000. Finally, High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $114.04 on Friday. The stock has a 50-day simple moving average of $115.94 and a 200 day simple moving average of $113.60. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14. The stock has a market capitalization of $281.65 billion, a price-to-earnings ratio of 32.12, a P/E/G ratio of 2.56 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter last year, the company posted $2.22 EPS. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Wall Street Analyst Weigh In

Several research firms recently commented on MRK. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Citigroup assumed coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target on the stock. Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.